NasdaqCM - Nasdaq Real Time Price USD

iBio, Inc. Common Stock (IBIO)

0.8483

+0.0907

+(11.97%)

As of 11:36:49 AM EDT. Market Open.

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

In-Licensing of novel activin E antibody underscores iBio’s commitment to delivering meaningful benefits to patients living with obesity and cardiometabolic diseasesSAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class antibody targeting Activin E, which was discovered using iBio’s patented Machine-Learning Antibody Engine. Activin E

GlobeNewswire 2 days ago

IBIO
+11.97%
iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist iBio remains on track to submit a regulatory submission for IBIO-600 in Q1 2026 SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven i

GlobeNewswire 17 days ago

IBIO
+11.97%
iBio to Begin Trading on the Nasdaq Stock Exchange

SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio’s common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol “IBIO.” The Company’s common stock will continue to

GlobeNewswire 2 months ago

IBIO
+11.97%
Is Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year?

We recently published a list of 10 Stocks Insiders Are Buying This Year. In this article, we are going to take a look at where Ibio, Inc. (NYSEAMERICAN:IBIO) stands against other stocks that insiders are buying this year. Even though this is just the beginning of the year, we thought it might be interesting to […]

Insider Monkey 2 months ago

IBIO
+11.97%
iBio Reports Fiscal Second Quarter 2025 Financial Results

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress. “In our second fiscal quarter we further strengthened our leadership with key Board appointments, reinforcing our commitment to innovation and execution as we work to develop next-generation therapeutics,” said CEO and Chief Scientific Officer Dr. Martin Brenner, Ph.D. “Following more recent development

GlobeNewswire 2 months ago

IBIO
+11.97%
iBio Announces New Investments from Board Members and Officers

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the closing of a private placement offering with members of its Board of Directors and Officers, totaling over $650,000. “We are grateful for the investments from our Board of Directors, which underscore their confidence and support in our strategy to advance as a clinical-stage biotech focused on developing therapeutics for cardiometabolic diseases

GlobeNewswire 3 months ago

IBIO
+11.97%
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

Achievement strengthens iBio’s partnered cardiometabolic and obesity program while showcasing its proprietary AI-driven drug and target discovery platform potentialSAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity usin

GlobeNewswire 3 months ago

IBIO
+11.97%
iBio Expands Pipeline with New Antibody Agreement

An update from Ibio ( (IBIO) ) is now available. iBio, Inc. announced an exclusive agreement with AstralBio to license a long-acting anti-myostatin antibody, IBIO-600, designed for obesity and cardiometabolic disorders. This agreement involves an upfront payment of $750,000 in stock and potential milestone payments up to $28 million. The collaboration enables iBio to expand its treatment programs, leveraging its proprietary technology for developing a bispecific antibody targeting myostatin/acti

TipRanks 3 months ago

IBIO
+11.97%
Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform

On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio, Inc. In March, iBio collaborated with AstralBio to discover, engineer, and develop antibodies to treat obesity and other cardiometabolic conditions. The antibody, now named IBIO-600, was identified by AstralBio using iBio’s proprietary technology stack. It was designed for subcutaneous administration and has t

Benzinga 3 months ago

IBIO
+11.97%
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific Antibody Designed to Promote Weight Loss, Prevent Muscle Loss and Weight Regain, Potentially Enabling Less Frequent Dosing than Current Obesity TreatmentsSAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and obesity treatment development pr

GlobeNewswire 3 months ago

IBIO
+11.97%
iBio Strengthens Board with Appointment of Two New Independent Directors

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and António Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. “These appointments expand and strengthen our board to align with iBio’s vision of becoming a next-generation antibody discovery and development company with a robust clinical pi

GlobeNewswire 4 months ago

IBIO
+11.97%
iBio Reports Fiscal First Quarter 2025 Financial Results

Advanced myostatin program with dosing underway in non-human primate studySAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. “In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progre

GlobeNewswire 5 months ago

IBIO
+11.97%
iBio and AstralBio Provide Update on Myostatin Program for Obesity

Lead molecule identified with potential extended half-life and subcutaneous dosingSAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today provided an update on the myostatin program for cardiometabolic disease and obesity in collaboration with AstralBio. iBio’s technology stack enabled the Company to rapidly advance the joint myostatin program from inception to in vitro proof-of-concept in human muscle cells. Follo

GlobeNewswire 6 months ago

IBIO
+11.97%
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update. “Our fiscal year 2024 was a transformational year for iBio, as we’ve solidified our business and financial position as a next-generation antibody company with a machine-learning-enabled platform for designing and developing difficult-to-drug therapeutics,

GlobeNewswire 6 months ago

IBIO
+11.97%
iBio to Participate in Upcoming Investor Conferences

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., and Chief Financial Officer, Felipe Duran, will participate in upcoming investor conferences. Dr. Brenner will give a virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference, held at the Lotte New York Palace Hotel in New York City, September 9-11, 2024.

GlobeNewswire 7 months ago

IBIO
+11.97%
iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Life sciences industry veteran to lead strategic alliances for iBio’s machine learning platform for antibody discovery and pipeline of cardiometabolic targetsSAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of Kristi Sarno as senior vice president, business development. Ms. Sarno brings more than 25 years of business development and strategic experience in the life sciences industry

GlobeNewswire 8 months ago

IBIO
+11.97%
iBio Closes Sale of Manufacturing Facility in Texas

– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapeutics, today announced the closing of the sale of its manufacturing facility located in Bryan, Texas (the “Property”) to the Board of Regents of the Texas A&M University System for $8.5 million. Following

GlobeNewswire 10 months ago

IBIO
+11.97%
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Strengthened cash position with investment by healthcare specialist investorsExpanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial results for the third quarter ended March 31, 2024 and provided a corporate update. “In our third fiscal quarter, we continued to advance toward our goal

GlobeNewswire 11 months ago

IBIO
+11.97%

Performance Overview

Return	IBIO	S&P 500 (^GSPC)
YTD	-65.38%	-7.42%
1-Year	-55.35%	+7.36%
3-Year	-99.47%	+27.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

iBio, Inc. Common Stock (IBIO)

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio to Begin Trading on the Nasdaq Stock Exchange

Is Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year?

iBio Reports Fiscal Second Quarter 2025 Financial Results

iBio Announces New Investments from Board Members and Officers

iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

iBio Expands Pipeline with New Antibody Agreement

Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

iBio Strengthens Board with Appointment of Two New Independent Directors

iBio Reports Fiscal First Quarter 2025 Financial Results

iBio and AstralBio Provide Update on Myostatin Program for Obesity

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

iBio to Participate in Upcoming Investor Conferences

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

iBio Closes Sale of Manufacturing Facility in Texas

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Performance Overview